antibody; mRNA, messenger RNA; PLIN2, perilipin 2; PNPLA3, patatin-like phospholipase-domain containing protein 3; SEM, standard error of the mean; TG, triglycerides; Tg, transgene; VLDL, very low density lipoprotein; WT, wild-type.
Soumik BasuRay, 1,2 Eriks Smagris, 1,2 Jonathan C. Cohen, 2 and Helen H. Hobbs [1] [2] [3] A sequence variation (I148M) in patatin-like phospholipase domain-containing protein 3 (PNPLA3) is strongly associated with fatty liver disease, but the underlying mechanism remains obscure. In this study, we used knock-in (KI) mice (Pnpla3 148M/M ) to examine the mechanism responsible for accumulation of triglyceride (TG) and PNPLA3 in hepatic lipid droplets (LDs). No differences were found between Pnpla3 148M/M and Pnpla3 1/1 mice in hepatic TG synthesis, utilization, or secretion. These results are consistent with TG accumulation in the Pnpla3 148M/M mice being caused by impaired TG mobilization from LDs. Sucrose feeding, which is required to elicit fatty liver in KI mice, led to a much larger and more persistent increase in PNPLA3 protein in the KI mice than in wild-type (WT) mice. Inhibition of the proteasome (bortezomib), but not macroautophagy (3-methyladenine) , markedly increased PNPLA3 levels in WT mice, coincident with the appearance of ubiquitylated forms of the protein. Bortezomib did not increase PNPLA3 levels in Pnpla3 148M/M mice, and only trace amounts of ubiquitylated PNPLA3 were seen in these animals. Conclusion: These results are consistent with the notion that the 148M variant disrupts ubiquitylation and proteasomal degradation of PNPLA3, resulting in accumulation of PNPLA3-148M and impaired mobilization of TG from LDs. (HEPATOLOGY 2017; 66:1111 -1124 ).
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F atty liver disease (FLD) is a burgeoning health problem due to the increased prevalence of both obesity and insulin resistance. The most significant and frequent genetic variation associated with hepatic steatosis is a nonsynonymous variant in the gene encoding patatin-like phospholipase-domain containing protein 3 (PNPLA3). (1) Substitution of methionine for isoleucine at residue 148 is strongly associated with not only with hepatic accumulation of triglyceride (TG), but also the full spectrum of both nonalcoholic FLD and alcoholic FLD, (2) including hepatic inflammation and fibrosis (3) and hepatocellular carcinoma. (4) Despite the robust association between PNPLA3-I148M and FLD, the mechanistic basis of this relationship has not been fully defined. Molecular modeling of PNPLA3 predicts that the I148M substitution disrupts enzymatic activity. (5) In vitro assays using purified PNPLA3 are consistent with this prediction; the I148M substitution markedly decreases TG hydrolase activity. (5) These findings suggested that PNPLA3 functions as a hepatic TG hydrolase, and that the I148M substitution is a loss-of-function allele that causes fatty liver by impairing PNPLA3-mediated TG hydrolysis. (5) This model was brought into question by the finding that PNPLA3 knockout mice do not develop hepatic steatosis. (6, 7) Thus, the hepatic TG accumulation associated with PNPLA3-148M cannot be attributed to a simple loss of TG hydrolase activity in the liver.
In contrast to PNPLA3 knockout mice, transgenic mice overexpressing human PNPLA3-148M (PNPLA3Tg 148M/1 mice) have significantly increased liver TG content, suggesting that the variant may confer a gain-of-function. (8) Further support for this notion came from the finding that PNPLA3 has lysophosphatidic acid acyltransferase (LPAAT) activity and that the PNPLA3-I148M is associated with an increase in TG synthesis. (9) However, we failed to observe LPAAT activity associated with PNPLA3 expression either in vitro or in vivo in PNPLA3Tg 148M/1 mice. (5, 8) Therefore, the hepatic steatosis associated with the 148M variant cannot be explained by simple loss-or gain-offunction models. The available data suggest that hepatic steatosis requires the presence of a catalytically dead (or significantly impaired) protein that interferes with mobilization of TG from lipid droplets (LDs). Thus, the variant causes fatty liver due to a combination of conferring both a loss-of-function and a gain-of-function.
To test this hypothesis, we introduced the susceptibility variant (148M) and a catalytically inactive variant (S47A) into mouse Pnpla3. (10) Both lines developed hepatic steatosis when fed a high-sucrose diet (HSD) (no.901683; 74% kilocalories from sucrose; MP Biomedicals, Santa Ana, CA). We also found that the PNPLA3 protein accumulates on LDs in sucrose-fed Pnpla3 148M/M and in Pnpla3 47A/A mice, but not in Pnpla3 1/1 mice. We performed metabolic studies to further define the effects of PNPLA3-148M on TG synthesis, oxidation, and secretion and to pinpoint the pathway responsible for the accumulation of the 148M protein on LDs.
Materials and Methods

ANIMALS
PNPLA3 knock-in (KI) mice in which methionine was substituted for isoleucine at codon 148 [Pnpla3 148M/M , also referred to as KI mice in this article], or in which alanine was substituted for the catalytic serine at residue 47 (Pnpla3 47A/A ), and mice expressing a human PNPLA3-WT or PNPLA3-148M transgene (Tg) (PNPLA3Tg WT/1 and PNPLA3Tg 148M/1 ) were generated as described previously. (8, 10) The transgenic mice used in the experiments were offspring of heterozygous X wild-type (WT) matings, and the non-Tg littermates were used as controls. The KI mice were backcrossed into C57Bl/6J mice for six generations. Mice were housed in microisolator and shoebox cages with 7090 sanichip bedding (Harlan Teklad, Houston, TX). All animal experiments were performed with the approval of the Institutional Animal Care and Research Advisory Committee at the University of Texas Southwestern Medical Center in Dallas, Texas.
Mice were maintained on a 12/12-hour light (8 AM to 8 PM)/dark cycle (8 PM to 8 AM) and fed Teklad Mouse/Rat Diet 7001 chow diet (Harlan Teklad, Houston, TX) ad libitum. For the dietary challenge studies, mice were fed an HSD for 4 weeks unless stated otherwise. Before each experiment, the mice were metabolically synchronized using one of two protocols: protocol 1 comprised 12 hours of fasting (8 AM to 8 PM, light) and 12 hours of refeeding (8 PM to 8 AM, dark) and protocol 2 comprised 18 hours of fasting (2 PM to 8 AM) and 6 hours of refeeding (8 AM to 2 PM).
ARTICLE INFORMATION:
ANTIBODIES
Mouse anti-human (h) PNPLA3 monoclonal antibodies (mAb) (clones 4C12 and 11C5) were raised against a recombinant fusion protein of hPNPLA3 and trigger factor. (11) A rabbit anti-mouse (m) PNPLA3 mAb was developed using a peptide corresponding to residues 454-927 (clone 19A6). The following commercial antibodies were used for immunoblotting: mouse anti-ubiquitin mAb (P4D1; Santa Cruz Biotech, Inc., 1:500), rabbit anti-mATGL (Cell Signaling Technology, MA, 1:1,000), guinea pig anti-mPLIN2 (Fitzgerald Industries International, Acton, MA, 1:5000), goat anti-mPNPLA3 polyclonal antibody (R&D Systems, Minneapolis, MN, 1:1000), mouse anti-hCGI-58 mAb (Abnova, Walnut CA, 1:5,000), and rabbit anti-phospho-S6 ribosomal protein polyclonal antibody (Cell Signal Technology, Danvers, MA). Secondary antibodies used for immunoblotting included goat anti-rabbit immunoglobulin G (IgG), goat anti-mouse IgG, or F ab fragment-specific horseradish peroxidase conjugated antibodies (Jackson Laboratories, West Grove, PA, 1:3,000).
LIVER CHEMISTRIES
Lipids were extracted from livers (100 mg). Cholesterol and TGs were measured using enzymatic assays (Infinity, Thermo Electron, Madison, WI, and Wako, Richmond, VA, respectively). (12) Values were normalized to sample weight. Lipids were separated into cholesterol esters, TGs, and phospholipids using thin-layer chromatography. (13) Bands were excised and lipids were measured as described. (8) 
IN VIVO LIPID SYNTHESIS STUDIES AND VERY LOW DENSITY LIPOPROTEIN SYNTHESIS STUDIES
Incorporation of tritum from tritiated water ( 3 H-H 2 O) into fatty acids, phosphatidic acid (PA), and TG was measured in sucrose-fed mice. Feeding was synchronized for 3 days (protocol 1). On the third day, mice were fasted for 24 hours and stagger-fed for 4 hours before intraperitoneal administration of 3 H-H 2 O (50 mCi in 250 lL 0.9% NaCl). (14, 15) Sodium 14 C-palmitate-albumin (94.5 nmol/mouse; 118 3 10 3 dpm/nmol) was injected intravenously (IV). Thirty minutes after the injection, mice were anesthetized and killed. Venous blood (500 lL) and livers were collected. Radiolabeled lipids were measured in liver samples (200 mg) as described previously. (15) Very low density lipoprotein (VLDL) secretion and TG mobilization were measured as described previously. (16) 
FATTY ACID OXIDATION IN PRIMARY HEPATOCYTES
Feeding was synchronized in sucrose-fed mice (protocol 1). Mice were anesthetized using isoflurane in a glass chamber and primary hepatocytes were seeded at 6 3 10 4 cells per well on XF-24 cell culture plates (Seahorse Bioscience) and oxygen (O 2 ) consumption rates were measured exactly as described previously. (17) 
MESSENGER RNA EXPRESSION
Total RNA was prepared from mouse tissues as described. (18) RNA was extracted from the liver and levels of selected transcripts were measured using realtime polymerase chain reaction as described. (18) All reactions were done in triplicate. The relative amount of messenger RNAs (mRNAs) was calculated using the comparative threshold cycle method with mouse 36B4 as an internal control.
BORTEZOMIB AND 3-METHYLADENINE TREATMENT OF MICE
Bortezomib (LC Laboratories, Woburn, MA) (10 mg) was dissolved in ethanol (1 mL) to prepare a stock solution. The solution was diluted in 0.9% saline to a final concentration of 5% (vol/vol). Mice were fed an HSD for 3 days (protocol 1). On the third day, either bortezomib (1 mg/kg) or vehicle control (0.9% NaCl, 5% ethanol) was injected via the tail veins. Mice were then fed an HSD ad libitum for 5 hours before being killed.
Mice were also treated with 3-methyladenine (3-MA) as described previously (19, 20) with minor modifications. Mice were fed an HSD for 1 week and then injected intravenously with 3-MA (15 mg/kg) in PBS or with vehicle alone.
IMMUNOBLOTTING
Immunoblot analysis of liver lysates and LD proteins was performed as described previously. (21) Bands were visualized using West Pico Super Signal Chemiluminescent Substrate (Thomson Fisher Scientific, Waltham, MA) and quantified using the LICOR Odyssey Imaging System (LI-COR, Inc., Lincoln, NE).
IMMUNOPRECIPITATION OF PNPLA3
LDs were isolated (10) and the proteins were solubilized in buffer A [0.1% Fos-choline-13, 50 mM Tris-HCl, pH 7.5, 150 mM NaCl plus protease inhibitor (Roche)]. A total of 30 lg protein was incubated with rabbit anti-mouse PNPLA3 mAb (19A6) overnight at 48C. After 12 hours, 50 lL protein A/G agarose (Santa Cruz Biotechnology, Inc.) was added to the protein/antibody mixture and allowed to incubate at 48C for 3 hours. Beads were washed 3 times in buffer A without the detergent. Beads were boiled and immunoblotting was performed as described. (21) To avoid interference with the immunoglobulin heavy chain, goat anti-rabbit light chain IgG and goat antimouse light chain IgG and Fab fragment-specific horseradish peroxidase-conjugated secondary antibodies were used for detection.
Results
FATTY ACID AND TG SYNTHESIS IN Pnpla3 148M/M MICE
Previously, we showed that the I148M substitution in PNPLA3 is associated with hepatic steatosis in humans and in sucrose-fed mice. (1, 10) To determine whether the fatty liver is caused by an increase in TG synthesis, as has been suggested, (9) we compared rates of incorporation of 3 H from 3 H 2 O into fatty acids and TG in WT and KI mice. Tissues were collected 1 hour after injection of tritiated water into the peritoneal cavity, and lipids were extracted from the indicated tissues and saponified to release free fatty acids. Tritium incorporation into 3 H-fatty acids ( Fig. 1A) and TG ( Fig. 1B ) did not differ between the two lines in any of the tissues collected ( Fig. 1B) .
Kumari et al. (9) reported that PNPLA3 has LPAAT activity and that the I148M variant was associated with an increase in that activity. Those authors suggested that the steatosis associated with PNPLA3-148M is caused by increased formation of PA from lysophosphatidic acid, leading to increased TG synthesis. We failed to detect a difference between the KI and WT mice in incorporation of tritium into PA (Fig. 1C) .
To compare the rates of TG synthesis from circulating fatty acids, we infused sodium 14 C-palmitate-albumin (94.5 nmol) into sucrose-fed WT and KI mice. The mice were killed after 30 minutes and the amount of 14 C-TG in the livers was quantified. No significant difference in the rate of appearance of 14 C-TG was found between the lines (Fig. 1D ).
Thus, we found no evidence that PNPLA3-148M causes fatty liver by promoting synthesis of TG from either endogenously synthesized or circulating fatty acids.
VLDL-TG SECRETION AND HEPATIC FATTY ACID OXIDATION IN Pnpla3 148M/M MICE
To determine whether VLDL secretion is compromised in Pnpla3 148M/M mice, as occurs in mice with a sequence variant in TM6SF2 that confers susceptibility to FLD, (21) we inhibited lipolysis of circulating TG by infusing Triton WR-1339 (500 mg/kg) after a 4-hour fast, and then monitored the appearance of TG in the circulation. (16) The rates of TG secretion did not differ significantly between sucrose-fed WT and KI mice ( Fig. 2A ). Thus, these data do not support the notion that the accumulation of TG associated with PNPLA3-148M expression is caused by a defect in the incorporation of TG into VLDL or in the secretion of VLDL-TG from the liver.
We also measured and compared rates of fatty acid oxidation in primary hepatocytes from KI and WT mice using the Seahorse XF-24 Analyzer. (17) Rates of O 2 consumption were similar in hepatocytes from the two lines, both at baseline and after addition of palmitate to the medium (Fig. 2B ). As expected, addition of etomoxir, which blocks entry of fatty acids into mitochondria, reduced O 2 consumption in both mouse lines.
The data in Figures 1 and 2 suggest that the fatty liver in sucrose-fed Pnpla3 148M/M mice was caused by reduced mobilization of TG from LDs, rather than by increased TG synthesis, decreased TG oxidation or decreased VLDL-TG secretion. Therefore, we examined the relationship between PNPLA3 mRNA and protein expression and TG mobilization after a prolonged fast in the two lines of mice.
RATE OF HEPATIC TG MOBILIZATION AFTER FASTING
WT and KI mice were fasted for 24 hours and then refed a chow diet. Fasting increased the level of liver TG 10-fold in both lines of mice ( Fig. 3 ), which is similar to what has been seen previously in C57Bl/6 mice. (14) With refeeding, levels of hepatic TG fell at similar rates in the WT and KI mice, returning to baseline within 9 hours.
Thus, we found no evidence that expression of PNPLA3-148M impairs mobilization of fatty acids from hepatic TG with refeeding after a prolonged fast. It could be argued that this result was predictable given that PNPLA3 is not expressed in the fasting state. (22) To address this issue, we monitored hepatic PNPLA3 levels during the transition from a fed state, when PNPLA3 is expressed, to a fasted state.
DELAYED CLEARANCE OF PNPLA3 DURING THE FED TO FASTING TRANSITION IN Pnpla3 148M/M (KI) MICE
Mice were fed an HSD for 3 days (protocol 1) before the food was removed. Livers were collected at the end of the last feeding cycle (time zero) and then at the indicated times. At the 2-hour time point, PNPLA3 levels were 25-fold higher in the KI mice than in the WT mice, despite only a 1.6-fold difference in mRNA levels (Fig. 4A ). As anticipated, PNPLA3 mRNA levels fell progressively over the 12hour fast. In the WT mice, PNPLA3 protein fell to , kidney, and blood of 11-to 13-week-old female PNPLA3-WT and PNPLA3-KI mice (n 5 10 per group). Mice were fed an HSD for 4 weeks and then feeding was synchronized for 3 days (protocol 1). During the last fasting cycle, the fast was extended to 24 hours. Mice were then stagger-fed at 4-hour intervals before being injected intraperitoneally with 3 H-H 2 O (50 mCi in 250 lL 0.9% NaCl). After 1 hour, the mice were killed and tissues were processed as described in Materials and Methods. Bars represent the mean 6 standard error of the mean (SEM). (D) Incorporation of 14 C-palmitate into hepatic TG in 12-week old female WT and KI mice (10/group). Mice were handled as described in panel A but were injected through the tail vein with 14 C-palmitate-BSA (200 lCi) and killed after 1 hour. Each bar represents the mean 6 SEM. Levels were compared among lines using a Student t test. The experiment was repeated once, and the results were similar. undetectable levels within 6 hours. In contrast, in the KI mice, PNPLA3 levels were maintained over the same time period. The PNPLA3 protein to mRNA ratio continued to increase over the first 9 hours of the experiment in the KI mice, thus revealing a significant dissociation of PNPLA3 mRNA and protein levels in the mice expressing the mutant protein.
In the same experiment, we examined the effects of fasting on mRNA and protein levels of two other LD proteins: adipocyte TG lipase (ATGL), the major lipase in LDs, (23) and perilipin 2 (PLIN2), an LD Blood was collected at the indicated time points, and plasma TG levels were measured. Mean plasma TG levels (6 SEM) at each point are shown. Rates of VLDL-TG secretion were determined by least square regression of plasma TG levels plotted against time. Slope estimates were determined from the linear portion of each graph and compared using a Student t test (P 5 0.52). The experiment was repeated once, and the results were similar. (B) Male mice (n 5 3 per group, age 11-12 weeks) were fed an HSD for 4 weeks and the feedings were synchronized for 3 days (protocol 1). The mice were killed at the end of the last refeeding cycle and primary hepatocytes were isolated. Oxygen consumption was measured in the primary hepatocytes using Seahorse XF-24 analyzer as described in Materials and Methods. Cells were treated with either etomoxir (300 lM), an inhibitor of carnitine palmitoyl transferase-1 or with BSA-palmitate (200 lM). Values represent the mean 6 SEM. **P < 0.01, ***P < 0.001. . At the end of the last feeding cycle, mice were fasted and killed at the indicated time points. Lipid droplets and mRNA were isolated from the liver as described in Materials and Methods. Real-time polymerase chain reaction was used to quantify selected mRNAs using 36B4 mRNA as a normalization standard. The level of PNPNLA3 mRNA in WT mice at time 0 was set at 1. LD proteins were precipitated using acetone, and immunoblotting was performed. Proteins (3 lg) were size-fractionated by way of 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and incubated with the following antibodies: anti-mPNPLA3 (19A6), anti-mATGL, and anti-mPLIN2 (see Materials and Methods for types of antibodies and dilutions). Signals were quantified using a LICOR system. (B) PNPLA3 accumulation on LDs after sucrose feeding. Male WT and KI mice (n 5 3 per group, age 12-14 weeks) were synchronized on a chow diet for 3 days (protocol 2). At the end of the last fasting cycle, the mice were fed an HSD for the indicated times and then killed. Livers were processed as described in Materials and Methods. The experiment was repeated once, and the results were similar. Values represent the mean 6 SEM. Levels were compared among lines using a Student t test. *P < 0.05. **P < 0.01. ***P < 0.001. ****P < 0.0001. protein that increases with TG accumulation in hepatocytes. (24) ATGL mRNA levels increased with fasting, as expected. (25) Despite the increase in ATGL mRNA, protein levels did not show a concomitant increase over the same time period. No correlation was found between the amount of PNPLA3 and ATGL on LDs. We also examined the levels of comparative gene identification 58 (CGI-58), a cofactor of ATGL; no significant differences were seen in the levels of CGI-58 between the two lines of mice until the last time point, when levels were marginally higher in the 148M mice (P 5 0.03) (Supporting Fig. S1 ). Thus, the FLD associated with PNPLA3-148M does not reflect a reduction in the amount of ATGL on LDs.
As a control for the experiment, we examined the effect of fasting on levels of PLIN2 mRNA and protein. The level of the PLIN2 transcript fell by 40% in the fasted animals. No consistent differences in PLIN2 protein were seen between the WT and KI mice over the course of the experiment.
Under the conditions of this experiment, no differences in hepatic TG levels were seen between the two lines of mice, except at the last time point, when the TG levels were modestly higher in the KI mice (Fig.  4A, bottom panel) . Thus, the changes in abundance of PNPLA3 that occurred acutely at the fed-to-fasting transition were associated with marginal differences in hepatic TG levels.
ACCUMULATION OF PNPLA3-148M ON LDs PRECEDES ACCUMUATION OF HEPATIC TG
Next, we examined PNPLA3 mRNA and protein levels in livers of mice transitioning from an ad libitum chow diet (protocol 2) to an HSD. Here, livers were collected at the end of the fasting cycle (time zero), when neither PNPLA3 mRNA nor protein were detectable, and then at the indicated times after mice were fed an HSD (Fig. 4B ). Levels of PNPLA3 mRNA increased dramatically within 6 hours of initiating sucrose feeding and continued to increase over the course of the experiment. Levels of PNPLA3 protein were 200-fold higher in KI mice than in WT mice at the 18-hour time point and remained significantly higher until the end of the experiment, despite comparable levels of PNPLA3 mRNA. PNPLA3 levels in total liver lysates were similar to those in the isolated LDs (Supporting Fig. S2 ), consistent with our prior observation that >90% of PNPLA3 expressed in hepatocytes is associated with LDs. (26) Despite the major differences in PNPLA3 content of LDs, the rates of accumulation of TG were similar in the two groups of mice. Thus, the effects of PNPLA3-148M on TG accumulation are not immediate and precede the development of hepatic steatosis.
To determine whether the increase in PNPLA3-148M displaces either ATGL or CGI-58 from LDs, we examined the levels of the two proteins. Both proteins accumulated on the droplet over the course of the experiment, but the accumulation was similar in WT and KI mice. Therefore, the higher TG content associated with chronic expression on PNPLA3-148M is not caused by displacement of ATGL or CGI-58 from the droplet. We cannot rule out the possibility that the presence of PNPLA3-148M interferes with the activity of ATGL or competes for binding of CGI-58.
REDUCED UBIQUITYLATION OF PNPLA3 IN LIVERS OF Pnpla3 148M/M MICE
We tested the hypothesis that PNPLA3-148M accumulates in the livers of Pnpla3 148M/M mice due to defective ubiquitylation of the protein. PNPLA3Tg WT/1 and PNPLA3Tg 148M/1 mice were fed an HSD for 3 days and given bortezomib (1 mg/kg) or vehicle control at the end of the feeding cycle. After 8 hours, the mice were killed and livers were collected. PNPLA3 mRNA levels did not change significantly with bortezomib treatment in either group (Supporting Fig.  S3A ). Bortezomib treatment was associated with a 15-fold increase in PNPLA3 protein levels in the mice expressing the human WT transgene. In contrast, no significant increase in PNPLA3-148M was seen in the bortezomib-treated PNPLA3Tg 148M/1 animals (Fig. 5A ). Levels of PLIN2 increased to a similar extent in both groups of transgenic mice as has been reported previously. (27) Bortezomib treatment was associated with TG accumulation in livers from both lines of transgenic mice (Supporting Fig. S3B, left) . A similar increase in hepatic TG was seen in Pnpla3 1/1 and in Pnpla3 -/mice (Supporting Fig. S3B, right) . Thus, the increase in TG associated with bortezomib treatment cannot be attributed to differences in PNPLA3 (or PLIN2) levels on hepatic LD in the two lines of mice. It remains possible that the increase in both PNPLA3 and PLIN2 levels associated with bortezomib treatment is secondary to its effects on TG accumulation.
REDUCED UBIQUITYLATION OF PNPLA3-148M
Another possibility is that the accumulation of PNPLA3-148M was caused by a reduction in ubiquitylation of the protein. To test this hypothesis, we treated WT and KI mice with vehicle alone or with bortezomib and compared PNPLA3 levels after immunoprecipitation from LDs (Fig. 5B) . In WT mice, PNPLA3 levels were 20-fold higher in the FIG. 5. Ubiquitylation of PNPLA3 in vivo in PNPLA3Tg WT/1 and PNPLA3Tg 148M/1 mice. (A) Male PNPLA3 Tg mice (n 5 3 per group, age 11-13 weeks) were fed an HSD for 3 days (protocol 1). At 8 AM the mice were injected with bortezomib (1 mg/kg) and vehicle control (0.9% NaCl plus 5% ethanol) through the tail vein. After 8 hours, the mice were killed and livers were collected and processed as described in Materials and Methods. Each bar represents the mean 6 SEM. (B) Pnpla3 1/1 and Pnpla3 148M/M male mice (n 5 3 per group, age 12-14 weeks) were treated as described in panel A, except that the mice were killed after 5 hours. Liver samples were pooled and LDs were isolated as described in Materials and Methods. PNPLA3 was immunoprecipitated from the LD fraction, and immunoblot analysis was performed after the proteins (10% of input) were size-fractionated by way of 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis using an anti-mPNPLA3 and anti-ubiquitin mAb (see Materials and Methods for antibody type and dilution). Signals were quantified using a LICOR system. Each bar represents the mean 6 SEM. Levels were compared among lines using a Student t test. *P < 0.05. **P < 0.01. ****P < 0.0001. *Nonspecific band. The experiment was repeated twice, and the results were similar.
bortezomib-treated mice than in animals treated with vehicle alone. As was seen previously in Tg mice (Fig.  5A ), levels of PNPLA3 in mice treated with vehicle alone were much higher (503) in the Pnpla3 148M/M mice than in their WT counterparts. Levels of PNPLA3 in KI mice did not increase after treatment with the proteasomal inhibitor (Fig. 5B) .
Next, we compared the levels of ubiquitylation of PNPLA3 in the two groups of mice. The PNPLA3 that was immunoprecipitated from LDs was subjected to immunoblot analysis with an anti-ubiquitin antibody (Fig. 5B) . A ladder of bands was detected in the WT animals, but only after bortezomib treatment. This result is consistent with the notion that bortezomib treatment causes the accumulation of polyubiquitylated forms of the WT protein. Only a modest increase in the intensity of the higher molecular weight bands was seen in the bortezomib-treated Pnpla3 148M/ M animals (Fig. 5B ). The ratio of ubiquitylated PNPLA3 to total PNPLA3 was 20-fold greater in WT mice than in KI mice in the group of bortezomibtreated animals (Fig. 5B, right panel) .
REDUCED UBIQUITYLATION OF PNPLA3-47A
Previously, we showed that the TG hydrolase activity of PNPLA3 was inactivated by substitution of alanine for the catalytic serine at residue 47. (5) Mice homozygous for this variant (Pnpla3 47A/A ) phenocopy the 148M variant; the Pnpla3 47A/A mice accumulated PNPLA3 on LDs and developed hepatic steatosis on an HSD. (10) In our initial studies, sucrose feeding induced hepatic steatosis in mice heterozygous for the 148M (Pnpla3 148M/1 ) but not in mice heterozygous for the 47A variant (Pnpla3 47A/1 ). (10) To determine whether the 47A variant causes steatosis by a different mechanism, we repeated this experiment multiple times with greater numbers of sixth-generation animals. Sucrose-fed heterozygous and homozygous mice with the S47A substitution accumulated PNPLA3 on LD and developed hepatic steatosis (Fig. 6A ).
If the accumulation of PNPLA3 on LDs in Pnpla3 148M/M mice is due to defective ubiquitylation of the protein, then a similar defect in ubiquitylation should be seen in Pnpla3 47A/A mice. To determine whether this was the case, we performed the experiment shown in Fig. 6B in the Pnpla3 148M/M and Pnpla3 47A/A mice. Bortezomib treatment was associated with a 9-fold increase in PNPLA3 protein levels in the WT animals. Immunoblotting with an anti-ubiquitin antibody revealed a ladder of higher molecular weight bands in the bortezomib-treated animals. A more modest increase in PNPLA3 was seen with bortezomib treatment in the Pnpla3 148M/M and Pnpla3 47A/ A mice (1.6-fold and 1.5-fold, respectively). No higher molecular weight bands were detected when the immunoprecipitates from these mice were blotted with an anti-ubiquitin antibody.
NO CHANGE IN PNPLA3 LEVELS IN MICE TREATED WITH 3-MA
We also treated the mice with 3-MA to inhibit macroautophagy. (28) 3-MA treatment was associated with a reduction in the levels of phosphorylated ribosomal protein S6, as expected, (29) but it had no effect on hepatic levels of PNPLA3 or TG in either group of transgenic animals ( Fig. 7 and Supporting Fig. S4 ).
Discussion
A major finding of this paper is that the I148M substitution in PNPLA3 does not cause hepatic steatosis either by increasing TG synthesis or by reducing TG disposal through fatty acid oxidation or VLDL-TG secretion. We also show that the 148M variant alters posttranslational modification of PNPLA3. In mice, treatment with the proteasome inhibitor bortezomib increased hepatic PNPLA3-WT levels 15-fold ( Fig.  6A) , coincident with the accumulation of polyubiquitylated forms of the protein. This finding indicates that ubiquitylation and proteasomal degradation is the major catabolic pathway for PNPLA3-WT. Bortezomib treatment had little effect on the levels of PNPLA3-148M, and a much smaller fraction (1/20) of the variant protein was poly-ubiquitylated (Figs. 5B and 6B). Taken together, our data are consistent with a model in which the WT form of PNPLA3 is efficiently ubiquitylated and rapidly turned over by proteasomal degradation. In contrast, PNPLA3-148M evades ubiquitylation and proteasomal degradation, resulting in accumulation of PNPLA3-148M and impaired TG mobilization from LDs.
Like other genes involved in TG metabolism, PNPLA3 is a target of the transcription factor sterol regulatory element binding protein 1c and is strongly up-regulated by carbohydrate feeding. (22) Despite the coordinate regulation of these genes, our data are not consistent with the notion that the fatty liver associated with PNPLA3 is due to an increase in endogenous FIG. 6. Ubiquitylated PNPLA3 in LDs of Pnpla3 1/1 , Pnpla3 47A/A , and Pnpla3 148M/M mice. (A) Pnpla3 1/1 , Pnpla3 S47A/1 , and Pnpla3 S47A/A female mice (n 5 8 per group, age 13-16 weeks) were fed an HSD for 4 weeks and then feedings were synchronized for 3 days (protocol 1). Mice were killed after the last refeeding cycle, and the livers were collected for lipid analyses and LD isolation. (B) Pnpla3 1/1 , Pnpla3 148M/M , and Pnpla3 47A/A female mice (n 5 3 per group per time point, age 11-13 weeks) were fed an HSD for 3 days, and the feedings were then synchronized (protocol 1). After the last refeeding cycle, mice were injected with bortezomib as described in Figure 5 . Mice were killed after 5 hours, and the livers were collected and pooled. LDs were isolated and samples were processed exactly as described in Figure 5B . Each bar represents the mean 6 SEM. Levels were compared among lines using a Student t test. **P < 0.01. ***P < 0.001. ****P < 0.0001. The data are representative of three independent experiments. synthesis of fatty acids or TGs. The incorporation of 3 H-H 2 0 into fatty acids, PA, and TG was not increased in sucrose-fed Pnpla3 148M/M mice (Fig. 1 ).
An alternative possibility is that the I148M variant causes a decrease in VLDL-TG secretion. Mutations in genes required for secretion of TG-rich lipoproteins (VLDL) from the liver lead to decreased plasma TG levels and fatty liver. (30, 31) Pirazzi et al. (32) reported that PNPLA3-148M is associated with reduced plasma TG levels in very obese individuals, suggesting the possibility that the steatosis is caused by a reduction in VLDL-TG secretion. Rates of VLDL-TG appearance into the circulation were essentially identical in WT and PNPLA3-148M KI mice (Fig. 2) . Whereas we cannot exclude the possibility that the PNPLA3-148M is associated with a decrease in VLDL-TG secretion under some conditions, our data are not consistent with an essential role for PNPLA3 in VLDL secretion.
In previous studies, we showed that the TG lipase activity of PNPLA3 is impaired by I148M substitution. (5) In primary hepatocytes prepared from mice expressing WT and mutant human PNPLA3 transgenes, overexpression of the 148M protein was associated with a reduction in glycerol release. (8) These findings are consistent with the hypothesis that I148M substitution impairs mobilization of TG from hepatic LDs. To further evaluate this hypothesis, we took advantage of the observation that mice subjected to prolonged fasting (24 hours) develop hepatic steatosis, which resolves rapidly upon refeeding. (14) This response provides a bioassay for the mobilization of liver TG. The changes in liver TG associated with refeeding after a prolonged fast did not differ between KI and WT animals (Fig. 3) . The result suggests that the 148M mutation does not impair TG mobilization in fasted animals. However, hepatic expression of PNPLA3 is very low in fasted mice. This finding, taken together with the observation that inactivation of Pnpla3 does not cause hepatic steatosis, is consistent with our prior observation that the PNPLA3-I148M is not purely a loss-of-function mutation. PNPLA3-148M expression is required for PNPLA3-associated hepatic steatosis.
The model we have developed based on our finding that accumulation of PNPLA3-148M on LDs impairs mobilization of TG from the droplets is congruent with the results of studies of PNPLA3 in cultured cells. We have shown previously that PNPLA3 is predominantly located on LDs and that expression of PNPLA3-148M is associated with droplets of larger size and with impaired cellular TG hydrolysis. (26) Chamoun et al. (33) also found that PNPLA3 is targeted to LDs and that cells expressing PNPLA3-148M have larger droplets. More recently, Ruhanen et al. (34) found that PNPLA3-148M is preferentially located on LDs compared with PNPLA3-WT when expressed in cultured cells and that expression of the mutant protein is associated with reduced TG turnover. We found no evidence that PNPLA3 interferes with ATGL activity by displacing it from the droplet.
Previously, we showed that PNPLA3 is tightly regulated by dietary carbohydrates. (22) PNPLA3 mRNA, which is expressed at very low levels during fasting, is robustly up-regulated by food intake. (22) In the present study, we performed the converse experiment and examined the effect on fasting on PNPLA3 levels in FIG. 7. Hepatic PNPLA3 levels in 3-MA-treated mice expressing human PNPLA3-WT and -148M. Male PNPLA3Tg WT/1 and PNPLA3Tg 148M/1 mice (n 5 3 per group, age 11-13 weeks) were fed an HSD for 1 week. Feeding was synchronized (protocol 1), and at the end of the third feeding cycle, the mice were treated with 3-MA (15 mg/kg) and fasted for 3 hours before being killed. LDs were harvested from the liver and immunoblotting was performed as described in Materials and Methods. Phospho-S6 ribosomal protein was used as a positive control. The data are representative of two independent experiments. Each bar represents the mean 6 SEM. Levels were compared among lines using a Student t test. *P < 0.05. ***P < 0.001. mice fed an HSD to compare the turnover of the protein in KI and WT mice (Fig. 4A) . At the start of the experiment, the levels of PNPLA3 were >15-fold higher in the KI mice than in the WT animals. After 6 hours of fasting, no PNPLA3 was detectable in the livers of the WT animals; in contrast, PNPLA3 levels remained high in the livers of KI mice. Thus, significant posttranslational regulation of PNPLA3 occurs in WT mice in association with fasting and refeeding; the corresponding changes in PNPLA3 protein levels are greatly blunted by the 148M variant.
Our present data indicate that the 148M variant enables PNPLA3 to evade proteasomal degradation. The 148M protein is under-ubiquitylated relative to the WT protein ( Fig. 5B and 6B) . A similar accumulation of non-ubiquitylated PNPLA3 was seen in the mice expressing PNPLA3-47A ( Fig. 6B ). It is possible that these variants alter the conformation of PNPLA3 so that it is no longer recognized by the E3 ligase that ubiquitylates the WT protein. Both variants impair catalytic activity by decreasing the V max of the enzyme and neither is expected to impair substrate binding. (5) It is possible that the uncleaved substrate remains bound to the enzyme and traps it in a conformation that is not recognized by the E3 ligase. An alternative possibility is that these variants are rapidly de-ubiquitinylated, thus resulting in accumulation of the protein.
It remains possible that the loss of catalytic activity of PNPLA3-148M and -47A may trap the mutant proteins on LDs and prevent their translocation to the proteasome. Binding to LDs decreases proteasomal degradation of several LD proteins. (35, 36) Accumulation of the 148M and S47A isoforms may reflect changes in the composition of the droplet surface that increase the affinity of PNPLA3-148M for LDs. However, trapping due to changes in the droplet surface seems unlikely given that levels of other LDassociated proteins, such as perilipin 2 and ATGL, were not increased in the KI mice ( Fig. 4) .
Protein degradation in eukaryotic cells is mediated by two mechanistically distinct systems: the 26S proteasome, which catalyzes the targeted degradation of tightly regulated, short-lived proteins, and autophagy, which degrades long-lived proteins and organelles. (37) The observation that PNPLA3-WT is rapidly turned over by proteasomal degradation is consistent with this model. Treatment with bortezomib increased PNPLA3 levels in WT mice, but even after 8 hours the levels of PNPLA3 in the treated animals failed to equal those seen in untreated Pnpla3Tg 148M/1 mice. It is possible that the inhibition of proteasome activity by bortezomib is incomplete at the dose used in our study, but we cannot exclude the possibility that other degradation pathways contribute to PNPLA3 turnover. Levels of PNPLA3-WT protein were not increased by administration of 3-MA, arguing against a role for macroautophagy. However, we cannot rule out that under other conditions, autophagy may contribute to PNPLA3 degradation. (38) Further studies to identify the specific residues on PNPLA3 that undergo poly-ubiquitylation will be required to further elucidate the specific mechanisms by which the 148M variant evades degradation.
The present findings have therapeutic implications for FLD. If the mechanistic basis for PNPLA3-148Massociated steatosis is similar in mice and humans, then agents that decrease PNPLA3 protein levels are likely to be efficacious in carriers, but not in individuals with two WT alleles. Conversely, agents that inhibit PNPLA3 activity are likely to exacerbate steatosis in individuals with PNPLA3-WT alleles. We have shown that human PNPLA3-WT is ubiquitylated when expressed in mice ( Fig. 5 ) or human liver cells (22) and that the human PNPLA3-148M isoform accumulates on LDs when expressed in the livers of mice. (10) Therefore, it appears likely that the 148M substitution promotes steatosis by similar mechanisms in mice and humans.
